Sickle Cell Disease
Anemia Management
A phase 1b/2 study of the efficacy and safety of combination hydroxyurea and dose-escalated erythropoietin for treatment of anemia in sickle cell disease (ACHiEvE-SCD). (opens new window)
Source: Blood 2024;144(Suppl 1):178-9.
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (opens new window)
Source: Eur J Haematol 1996;56(5):326-8.
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (opens new window)
Source: Acta Haematol 1995;94(3):128-34.
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (opens new window)
Source: Haematologica 2006;91(8):1076-83.
Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (opens new window)
Source: J Obstet Gynaecol 2007;27(1):82-3.
The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (opens new window)
Source: Am Surg 2009;75(12):1175-8.
